© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

Helomics® Corporation and The University of Pittsburgh Announce the Completion of a Broad Strategic Agreement to Co-Develop and Commercialize University Technologies

March 21, 2017

 

 

The University’s Innovation Institute will collaborate with Helomics to co-develop new intellectual property and to commercialize existing University technologies.

 

 

PITTSBURGH– March 21, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and The University of Pittsburgh - Of the Commonwealth System of Higher Education (Pitt), today announced the completion of a Master Research and Development Collaboration Agreement.  Under the terms of this five-year agreement, Helomics will collaborate with the University’s Innovation Institute to co-develop new intellectual property and to commercialize existing University intellectual property and technologies.

 

Marc S. Malandro, PhD, CLP, RTTP, Founding Director of the Innovation Institute and Vice Chancellor for Technology Management and Commercialization at the University of Pittsburgh commented, “We look forward to collaborating with one of Western Pennsylvania’s leading biotechnology companies to provide real-world validation of Pitt technologies in the areas of diagnostics and personalized medicine.  This new alliance reflects the University’s strategic priority to create mutually beneficial partnerships for commercializing our discoveries and technologies.”

 

“We are very excited about this strategic collaboration with the University of Pittsburgh and the Innovation Institute,” stated Gerald J. Vardzel Jr., President and CEO of Helomics.  “The University of Pittsburgh is one of the leading academic and biomedical research universities in the world.  This collaboration with the University will be instrumental to Helomics in achieving our mission of improving the standard of care for patients by bringing unique diagnostic tests and technologies to the market.”    

 

About Helomics® Corporation

Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client’s specific product development needs.

Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories.  For more information please visit: www.helomics.com.

 

 

About The University of Pittsburgh Innovation Institute

Established in 2013, The University of Pittsburgh Innovation Institute is the University’s hub for innovation and entrepreneurship.  The Innovation Institute provides a comprehensive suite of services for Pitt Innovators, from protecting intellectual property to the commercialization of new discoveries through licensing and/or new enterprise development. The Institute also provides a wealth of educational programming, mentoring and networking for Pitt faculty, students and partners.  The Innovation Institute is strengthening the culture of innovation and entrepreneurship at Pitt and is eager to facilitate and support entrepreneurial initiatives across the university. It is also invites alumni, entrepreneurs and industry partners to collaborate with our faculty and students to help achieve societal impact through commercialization.  Through the affiliated Institute for Entrepreneurial Excellence, the Innovation Institute also assists entrepreneurs throughout Western Pennsylvania in starting, growing or transitioning their businesses.  For more information please visit: www.innovation.pitt.edu

 

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.  

 

For more information regarding Helomics Corporation, please contact:

Michelle Murgia, Marketing Communications and Design

Helomics Corporation

mmurgia@helomics.com

412-432-1363

 

For more information regarding The University of Pittsburgh Innovation Institute, please contact:

Michael Yeomans, Marketing and Special Events Manager

The University of Pittsburgh Innovation Institute

myeomans@innovation.pitt.edu

(412) 624-4474

 

 

Sources: Helomics® Corporation and The University of Pittsburgh Innovation Institute

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

1/10
Please reload

Recent Posts
Please reload

Archive